1
|
Lopes ACDS, Sousa LPN, Silva RMME, Simões E Silva AC, Dusse LM, Alpoim PN. Hemostasis and oxidative stress in chronic kidney disease in children and adolescents. Can J Physiol Pharmacol 2022; 100:926-936. [PMID: 35613472 DOI: 10.1139/cjpp-2021-0714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Chronic kidney disease (CKD) can be defined as the progressive loss of renal function, characterized by decreased glomerular filtration rate (GFR). The etiology of CKD in childhood is mainly associated with congenital anomalies of the kidneys and urinary tract (CAKUT) and to glomerular diseases. The goal of this study was to investigate the hemostasis and oxidative stress in pediatric CKD of different etiologies. 54 CKD children and adolescents and 52 controls were enrolled in this study. The evaluation of hemostasis was carried out by determination of D-Dimer (D-Di) and plasminogen activator inhibitor (PAI-1) plasma levels, while oxidative stress by thiobarbituric acid reactive substances (TBARS) levels, protein carbonyl content, plasma antioxidant capacity (MTT) and ascorbate. The D-Di was increased in CAKUT stage 3 or 4 patients compared to those with glomerular disease. PAI-1 was increased in patients with glomerular disease compared to CAKUT. Carbonyl protein content was higher in the control group compared to glomerular disease stage 3 or 4 patients. Our findings showed that the reduction in GFR is associated with a state of hypercoagulability. The analysis of integrated networks showed an expansion of connections among hemostatic and oxidative stress markers in CKD children and adolescents comparing to controls.
Collapse
Affiliation(s)
| | | | | | | | | | - Patrícia Nessralla Alpoim
- UFMG, 28114, ACT, Faculdade de Farmácia Avenida Antonio Carlos Pampulha, Belo Horizonte, MG, Brazil, 31270-901;
| |
Collapse
|
2
|
Tian B, Deng Y, Cai Y, Han M, Xu G. Efficacy and safety of Combination Therapy with Sodium-glucose Transporter 2 Inhibitors and Renin-Angiotensin System Blockers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Nephrol Dial Transplant 2021; 37:720-729. [PMID: 33605424 DOI: 10.1093/ndt/gfab048] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND This study was designed to evaluate the efficiency and safety of combination therapy with SGLT2 inhibitors and RAS blockers, such as ACEI/ARB, in patients with T2DM. METHODS We searched PubMed, EMBASE, Web of Science and Cochrane Library from their inception to May 2020. Two authors independently performed study selection, risk of bias assessment and data extraction. The quality and risk of bias were assessed by the Cochrane Risk of Bias Tool. Statistical heterogeneity was qualified by the I-squared statistics. RESULTS Seven studies including 1757 patients were analyzed. Compared with ACEI/ARB alone, combination therapy with SGLT2 inhibitors and ACEI/ARB produced reduction in SBP (WMD -3.84 mmHg), DBP (WMD -1.06 mmHg), 24 h ambulatory SBP (WMD -4.59 mmHg), 24 h ambulatory DBP (WMD -2.08 mmHg), UACR(WMD -29.70%), eGFR (WMD -3.46 mL/min per 1·73 m2), HbA1c (SMD -0.48), FPG (SMD -0.28), uric acid (SMD -0.35), and body weight (SMD -0.29). The risk of hypoglycemia with combination therapy was higher than the control group (RR 1.37). As for the risk of total AEs, genital infection and urinary tract infection, no significant difference was revealed. CONCLUSION Compared with ACEI/ARB alone, the combination therapy with SGLT2 inhibitors and ACEI/ARB in T2DM was effective and well-tolerated, and could achieve additional effects, including better control of blood pressure, improvement of renal outcomes, alleviation of long-term renal function, and decrease of blood glucose and body weight. The combination therapy showed an increased risk of hypoglycemia.
Collapse
Affiliation(s)
- Beichen Tian
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yuanjun Deng
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yang Cai
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Min Han
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Gang Xu
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
3
|
Hallberg P, Nagy J, Karawajczyk M, Nordang L, Islander G, Norling P, Johansson HE, Kämpe M, Hugosson S, Yue QY, Wadelius M. Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough. Ann Pharmacother 2017; 51:293-300. [PMID: 27889699 DOI: 10.1177/1060028016682251] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Angioedema is a rare and serious adverse drug reaction (ADR) to angiotensin-converting enzyme (ACE) inhibitor treatment. Dry cough is a common side effect of ACE inhibitors and has been identified as a possible risk factor for angioedema. OBJECTIVE We compared characteristics between patients with ACE inhibitor-induced angioedema and cough with the aim of identifying risk factors that differ between these adverse events. METHODS Data on patients with angioedema or cough induced by ACE inhibitors were collected from the Swedish database of spontaneously reported ADRs or from collaborating clinicians. Wilcoxon rank sum test, Fisher's exact test, and odds ratios (ORs) with 95% CIs were used to test for between-group differences. The significance threshold was set to P <0.00128 to correct for multiple comparisons. RESULTS Clinical characteristics were compared between 168 patients with angioedema and 121 with cough only. Smoking and concomitant selective calcium channel blocker treatment were more frequent among patients with angioedema than cough: OR = 4.3, 95% CI = 2.1-8.9, P = 2.2 × 10-5, and OR = 3.7, 95% CI = 2.0-7.0, P = 1.7 × 10-5. Angioedema cases were seen more often in male patients (OR = 2.2, 95% CI = 1.4-3.6, P = 1.3 × 10-4) and had longer time to onset and higher doses than those with cough ( P = 3.2 × 10-10 and P = 2.6 × 10-4). A multiple model containing the variables smoking, concurrent calcium channel blocker treatment, male sex, and time to onset accounted for 26% of the variance between the groups. CONCLUSION Smoking, comedication with selective calcium channel blockers, male sex, and longer treatment time were associated with ACE inhibitor-induced angioedema rather than cough.
Collapse
Affiliation(s)
| | - Julia Nagy
- 2 The Ryhov County Hospital, Jönköping, Sweden
| | | | | | | | | | | | | | - Svante Hugosson
- 5 Örebro University Hospital and Örebro University, Örebro, Sweden
| | | | | |
Collapse
|
4
|
Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, Yue QY, Magnusson PKE, Wadelius C, Eriksson N, Wadelius M. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. Pharmacogenomics 2017; 18:201-213. [DOI: 10.2217/pgs-2016-0184] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Aim: We conducted a genome-wide association study on angiotensin-converting enzyme inhibitor-induced cough and used our dataset to replicate candidate genes identified in previous studies. Patients & methods: A total of 124 patients and 1345 treated controls were genotyped using Illumina arrays. The genome-wide significance level was set to p < 5 × 10-8. Results: We identified nearly genome-wide significant associations in CLASP1, PDE11A, KCNMB2, TGFA, SLC38A6 and MMP16. The strongest association was with rs62151109 in CLASP1 (odds ratio: 3.97; p = 9.44 × 10-8). All top hits except two were located in intronic or noncoding DNA regions. None of the candidate genes were significantly associated in our study. Conclusion: Angiotensin-converting enzyme inhibitor-induced cough is potentially associated with genes that are independent of bradykinin pathways.
Collapse
Affiliation(s)
- Pär Hallberg
- Department of Medical Sciences, Clinical Pharmacology & Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Matilda Persson
- Department of Medical Sciences, Clinical Pharmacology & Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Tomas Axelsson
- Department of Medical Sciences, Molecular Medicine & Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Marco Cavalli
- Department of Immunology, Genetics & Pathology & Science for Life Laboratory, Uppsala University, Sweden
| | | | - Hans-Erik Johansson
- Department of Public Health & Caring Sciences/Geriatrics, Uppsala University, Uppsala, Sweden
| | | | - Patrik KE Magnusson
- Swedish Twin Registry, Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm
| | - Claes Wadelius
- Department of Immunology, Genetics & Pathology & Science for Life Laboratory, Uppsala University, Sweden
| | - Niclas Eriksson
- Uppsala Clinical Research Center & Department of Medical Sciences, Uppsala University, Uppsala, Sweden
| | - Mia Wadelius
- Department of Medical Sciences, Clinical Pharmacology & Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| |
Collapse
|
5
|
de Jesús Romero-Prado MM, Curiel-Beltrán JA, Miramontes-Espino MV, Cardona-Muñoz EG, Rios-Arellano A, Balam-Salazar LB. Dietary flavonoids added to pharmacological antihypertensive therapy are effective in improving blood pressure. Basic Clin Pharmacol Toxicol 2014; 117:57-64. [PMID: 25441094 DOI: 10.1111/bcpt.12360] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 11/19/2014] [Indexed: 02/05/2023]
Abstract
Epidemiological studies have suggested that the daily intake of flavonoids is associated with a decreased risk of developing cardiovascular disease. Our purpose was to evaluate the effect of the addition of dietary flavonoids (DF) to antihypertensive treatment (AHT), based on telmisartan (Tms) or captopril (Cpr), on blood pressure (BP), body mass index (BMI), waist/hip ratio, leptin, lipid profile and inflammation in hypertensive young patients. An open-label, randomized, controlled trial was performed among 79 patients aged 20-55 years with grade I or grade II systemic arterial hypertension. The subjects were assigned to one of four groups for AHT plus DF during 6 months: Cpr (n = 14), Cpr + DF (n = 19), Tms (n = 25) and Tms + DF (n = 21). DF consisted of dark chocolate, dehydrated red apple and green tea in an infusion to obtain a daily dose of 425.8 ± 13.9 mg epicatechin equivalents. The BP and anthropometric parameters were measured every 2 weeks. Lipid profile, leptin and hsCRP were determined by standard methods. The combination AHT-DF produced an additional and significant reduction in (i) SBP/DBP of -5/-4 mmHg, being -7/-5 for Cpr + DF and -4/-3 for Tms + DF; (ii) triglyceride levels (-30.6%) versus AHT alone (-9.6%); and (iii) leptin: Cpr + DF versus Tms + DF (p < 0.005). Finally, C-reactive protein plasma levels were reduced significantly in all groups independently of the applied treatment. We conclude that the addition of flavonoids to pharmacological antihypertensive therapy shows additional benefits on BP, lipid profile, leptin, obesity and inflammation.
Collapse
Affiliation(s)
- Marina María de Jesús Romero-Prado
- Department of Physiology, INTEC, Universitary Center of Health Sciences (CUCS), Guadalajara, Jalisco, Mexico.,University of Guadalajara, Guadalajara, Jalisco, Mexico
| | - Jesús Aarón Curiel-Beltrán
- University of Guadalajara, Guadalajara, Jalisco, Mexico.,Department of Medical Sciences, Coast Universitary Center (CUCosta), Guadalajara, Jalisco, Mexico
| | - María Viviana Miramontes-Espino
- Department of Physiology, INTEC, Universitary Center of Health Sciences (CUCS), Guadalajara, Jalisco, Mexico.,University of Guadalajara, Guadalajara, Jalisco, Mexico
| | | | - Angeles Rios-Arellano
- Cardiology Service, Mexican Institute of Health Security, Regional Hospital No. 45, Guadalajara, Jalisco, Mexico
| | | |
Collapse
|
6
|
Wadelius M, Marshall SE, Islander G, Nordang L, Karawajczyk M, Yue QY, Terreehorst I, Baranova EV, Hugosson S, Sköldefors K, Pirmohamed M, Maitland-van der Zee AH, Alfirevic A, Hallberg P, Palmer CNA. Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system. Clin Pharmacol Ther 2014; 96:477-81. [PMID: 24960520 PMCID: PMC4172548 DOI: 10.1038/clpt.2014.138] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Accepted: 06/18/2014] [Indexed: 11/10/2022]
Abstract
Angioedema is a potentially life-threatening adverse reaction to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicenter recruitment of patients are needed. To reduce patient heterogeneity, we have standardized the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.
Collapse
Affiliation(s)
- M Wadelius
- Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - S E Marshall
- Medical Research Institute, College of Medicine, Dentistry and Nursing, University of Dundee, Ninewells Hospital, Dundee, UK
| | - G Islander
- Department of Intensive and Perioperative Care, Skåne University Hospital, Lund, Sweden
| | - L Nordang
- Department of Surgical Sciences, Otorhinolaryngology, and Head & Neck Surgery, Uppsala University, Uppsala, Sweden
| | - M Karawajczyk
- Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden
| | - Q-Y Yue
- Medical Products Agency, Uppsala, Sweden
| | - I Terreehorst
- Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands
| | - E V Baranova
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
| | - S Hugosson
- Department of Otorhinolaryngology, Örebro University Hospital and Örebro University, Örebro, Sweden
| | - K Sköldefors
- Department of Otorhinolaryngology, Hudiksvall Hospital, Hudiksvall, Sweden
| | - M Pirmohamed
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - A-H Maitland-van der Zee
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands
| | - A Alfirevic
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
| | - P Hallberg
- Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - C N A Palmer
- Medical Research Institute, College of Medicine, Dentistry and Nursing, University of Dundee, Ninewells Hospital, Dundee, UK
| |
Collapse
|
7
|
Galzerano D, Di Michele S, Paolisso G, Tuccillo B, Lama D, Carbotta S, Cittadini A, Tedesco MA, Gaudio C. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012; 13:496-503. [DOI: 10.1177/1470320312443909] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
| | - Sara Di Michele
- Department of Heart and Great Vessels, A Reale, La Sapienza University, Rome, Italy
| | - Giuseppe Paolisso
- Department of Geriatrics and Metabolic Disease, Second University, Naples, Italy
| | | | - Diana Lama
- Department of Geriatrics and Metabolic Disease, Second University, Naples, Italy
| | - Sabino Carbotta
- Department of Heart and Great Vessels, A Reale, La Sapienza University, Rome, Italy
| | - Antonio Cittadini
- Clinical Medicine and Cardiovascular Science Department, Federico II University, Naples, Italy
| | | | - Carlo Gaudio
- Department of Heart and Great Vessels, A Reale, La Sapienza University, Rome, Italy
| |
Collapse
|
8
|
Association of the angiotensin II type I receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. Hypertens Res 2010; 33:1137-43. [PMID: 20703234 DOI: 10.1038/hr.2010.156] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Mounting evidence suggests the potential susceptibility of individuals with a mutation in the angiotensin II type I receptor (AT1R) gene to hypertension. One polymorphism, +1166 A>C, has been extensively studied, but the results have often been irreproducible. We therefore aimed to meta-analyze all available case-control studies from the English language literature to explore the association of this polymorphism with hypertension. A total of 22 studies with 24 populations involving 8249 patients and 8225 controls were identified as of 25 February 2010. A random-effects model was performed regardless of the between-study heterogeneity. The study quality was assessed in duplicate. The data were analyzed using RevMan software (version 5.0.23). Overall, the presence of the +1166 C allele significantly conferred an increased risk of hypertension (odds ratio (OR)=1.14; 95% confidence interval, 1.00-1.30; P=0.05). Under the assumption of three genetic modes of inheritance, an elevated hypertension risk was observed for each comparison (codominant: AC vs. AA, OR=1.10 (P=0.20) and CC vs. AA, OR=1.21 (P=0.36); dominant: OR=1.13 (P=0.09); recessive: OR=1.21 (P=0.36)). Upon stratification by study design, more obvious associations were observed for the population-based design, whereas there were no changes in direction and only slight changes in magnitude upon stratification by sample size and geographical area. No publication biases were indicated by the fail-safe number. Our study pooled previous findings and showed that the AT1R +1166 C allele conferred an increased risk of hypertension. We suggest that confirmation in a large, well-designed study or from functional aspects of this polymorphism is critical.
Collapse
|
9
|
Omae K, Ogawa T, Nitta K. Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease. Heart Vessels 2010; 25:203-8. [PMID: 20512447 DOI: 10.1007/s00380-009-1188-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2009] [Accepted: 07/14/2009] [Indexed: 01/08/2023]
Abstract
Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) is recommended for the treatment of hypertension in patients with chronic kidney disease (CKD). The relation of ACEI to renal prognosis was investigated in CKD patients in a retrospective cohort study. The objectives were patients with nondiabetic CKD of stage 4 or below receiving monotherapy with calcium channel blocker (CCB), ACEI, or ARB, and combination therapy. For the endpoint of progression to CKD stage 5, Cox's proportional hazards analysis was conducted with explanatory variables of age, sex, baseline estimated GFR (eGFR), and proteinuria (UP) at the start of the observation period, and final blood pressure (BP) and UP at completion of the observation period. Analyzed patients comprised 131 males and 117 females, with mean age of 47.8 years. Patients were observed for 44.2 months, and the parameters of final SBP, DBP, eGFR, and UP were 127.6 +/- 6.9 mmHg, 77.8 +/- 5.8 mmHg, 38.1 +/- 10.6 ml/min/1.73 m(2), and 1.08 +/- 0.57 g/gCr, respectively, where 42 patients progressed to CKD stage 5. Drugs of CCB, ACEI, and ARB types were administered to 93, 85, and 127 patients, respectively. In the multivariate analysis, extracted common prognostic factors included the baseline eGFR and final UP, the odds ratio of which was 0.876 (every increase by 1 ml/min of eGFR) and 2.229 (every increase by 1 g of UP), respectively. Among drugs in use, ACEI was an independent prognostic factor, whose odds ratio was 0.147. The present study suggests that ACEI is a prognostic factor independent of hypotensive action and UP in CKD patients.
Collapse
Affiliation(s)
- Kiyotsugu Omae
- Department of Internal Medicine, Yoshikawa Hospital, Tokyo, Japan
| | | | | |
Collapse
|
10
|
Angiotensin Blockade Is Associated With Early Graft Dysfunction After Live Donor Renal Transplantation. Transplantation 2010; 89:707-9. [DOI: 10.1097/tp.0b013e3181c892f2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Weir MR. Are we "ONTARGET" yet with regard to optimal antihypertensive regimens? Curr Hypertens Rep 2008; 10:385-6. [PMID: 18775115 DOI: 10.1007/s11906-008-0071-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Interacting effect of genetic variants of angiotensin II type 1 receptor on susceptibility to essential hypertension in Northern Han Chinese. J Hum Hypertens 2008; 23:68-71. [PMID: 18633425 DOI: 10.1038/jhh.2008.77] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
13
|
Gluhovschi G, Gluhovschi C, Bob F, Velciov S, Trandafirescu V, Petrica L, Bozdog G. Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio- and neuroprotection. Acta Clin Belg 2008; 63:152-69. [PMID: 18714846 DOI: 10.1179/acb.2008.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Renal diseases induce nephroprotective measures that may affect the heart, brain and other organs. In addition, many cardiovascular and neurological diseases are accompanied by renal lesions. For these reasons, multiorgan-protective measures, including cardio-, reno- and neuro-protective measures, are necessary to treat these diseases. The drugs used in nephrology are often pleiotropic. Although they usually address a single organ or tissue, many of them have complex actions that may provide multiorgan-protection. The present paper aims to review 3 classes of drugs that are commonly prescribed in nephrological practice: statins, RAS blockers (such as ACEIs and ARBs) and erythropoietin (EPO). This paper highlights the renoprotective actions, as well as those that are protective of the heart, brain and other organs, of these drugs at the cellular and molecular level. Their protective actions are attributable to their main effects and pleiotropic effects. The protective pleiotropic actions of these drugs may be exerted on multiple organs, making them multiorgan-protective. Another objective is to analyse the shared multiorgan-protective pleiotropic effects of RAS blockers (ACEIs and ARBs), statins and erythropoietin. This will allow for the practical association of the main renoprotective drugs with multiorgan protection.
Collapse
Affiliation(s)
- G Gluhovschi
- Nephrology Department, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania.
| | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
Diabetes is currently one of the leading causes of end-stage renal failure requiring renal replacement therapy in the Western World. About 15% to 20% of type 1 diabetic patients and 30% to 40% of type 2 diabetic patients will eventually develop end-stage renal failure. To prevent the development or progression of diabetic kidney disease, good glycaemic control remains the cornerstone in the management of diabetic patients. Beyond glycaemic control, other metabolic factors have been shown to be involved in the development of diabetic kidney disease, i.e. advanced glycation endproducts (AGEs) and the aldose reductase pathway. Furthermore, an adequate control of high blood pressure and treatment of microalbuminuria are major therapeutic targes. To achieve adequate blood pressure control, a combination therapy with different classes of antihypertensive agents is often necessary, especially including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Other vasoactive factors involved in diabetic nephropathy such as endothelin and nitric oxide will be covered briefly. Besides hyperglycaemia and high blood pressure, other risk factors have been identified in the development or progression of diabetic kidney disease: smoking, hyperlipidaemia, obesity and high protein intake. Their impact on renal function will be highlighted. Finally, recent research has also identified intracellular pathways such as the diacylglycerol-protein kinase C pathway and several growth factors, such as growth hormone, insulin-like growth factor, transforming growth factor-beta, vascular endothelial growth factor, and platelet derived growth factor as players in diabetic kidney disease.
Collapse
Affiliation(s)
- B F Schrijvers
- Endocrinologie, Dienst voor Inwendige Ziekten, Universitair Ziekenhuis Gent, België.
| | | |
Collapse
|
15
|
Weir MR. Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. J Clin Hypertens (Greenwich) 2007; 6:315-23; quiz 324-5. [PMID: 15187494 PMCID: PMC8109693 DOI: 10.1111/j.1524-6175.2006.03473.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II receptor blocker to existing antihypertensive regimens reduces cardiovascular and renal risk, which may, in part, be a result of blocking the effects of angiotensin II. Though the antihypertensive dose response of these agents is well documented, the dose response for optimal target organ protection has not yet been clarified. A review of recent studies of angiotensin II receptor blockers in hypertension, acute myocardial infarction, heart failure, and nephropathy provide some data on specific drugs, doses, and risk reduction. Taken as a whole, these studies suggest the highest doses tested, which are at the upper limit of the antihypertensive range, provide greater risk reduction than lower doses. What is unknown is whether even higher doses or full-dose angiotensin II receptor blockers plus full-dose angiotensin-converting enzyme inhibitors might provide even greater risk reduction. Data from ongoing trials will provide additional insight.
Collapse
Affiliation(s)
- Matthew R Weir
- Department of Medicine, Division of Nephrology, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, MD 21201, USA.
| |
Collapse
|
16
|
Weir MR. Providing End‐Organ Protection With Renin–Angiotensin System Inhibition: The Evidence So Far. J Clin Hypertens (Greenwich) 2007; 8:99-105; quiz 106-7. [PMID: 16470078 PMCID: PMC8109700 DOI: 10.1111/j.1524-6175.2005.04648.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Much debate surrounds the question of the optimal therapeutic choices for medication to control blood pressure and reduce cardiovascular events. Experimental evidence suggests that drugs that block the renin-angiotensin system retard vascular disease through their direct ability to antagonize the effects of angiotensin II, which has vasoconstrictive, vascular proliferative, and atherosclerotic effects. It is not known how to separate the potential vascular protective effects of the drugs from their antihypertensive benefits. Clinical trial evidence indicates that achieved lower blood pressure goals almost always confer cardiovascular risk reduction advantages. There is also evidence, however, that successful antihypertensive regimens incorporating a renin-angiotensin system blocker, such as an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, provide more cardiovascular risk reduction benefit compared with regimens that do not incorporate a renin-angiotensin blocker. This includes composite or specific end points involving reduction of stroke, myocardial infarction, or development of end-stage renal disease.
Collapse
Affiliation(s)
- Matthew R Weir
- Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21202, USA.
| |
Collapse
|
17
|
Tanaka K, Ito M, Kodama M, Maruyama H, Hoyano M, Mitsuma W, Iino N, Hirono S, Okura Y, Gejyo F, Tanabe N, Aizawa Y. Longitudinal Change in Renal Function in Patients With Idiopathic Dilated Cardiomyopathy Without Renal Insufficiency at Initial Diagnosis. Circ J 2007; 71:1927-31. [DOI: 10.1253/circj.71.1927] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Komei Tanaka
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Masahiro Ito
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Makoto Kodama
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Hiroki Maruyama
- Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences
| | - Makoto Hoyano
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Wataru Mitsuma
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Noriaki Iino
- Department of Applied Molecular Medicine, Niigata University Graduate School of Medical and Dental Sciences
| | - Satoru Hirono
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Yuji Okura
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| | - Fumitake Gejyo
- Division of Clinical Nephrology, Niigata University Graduate School of Medical and Dental Sciences
| | - Naohito Tanabe
- Department of Community Preventive Medicine, Niigata University Graduate School of Medical and Dental Sciences
| | - Yoshifusa Aizawa
- Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences
| |
Collapse
|
18
|
Song JH, Cha SH, Hong SB, Kim DH. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens 2006; 24:S101-6. [PMID: 16601562 DOI: 10.1097/01.hjh.0000220414.99610.6b] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Despite the renoprotective effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), many patients with chronic kidney disease develop end-stage kidney disease. Combination treatment with an ACEI and an ARB is a recently introduced approach to obtain more complete blockade of the renin-angiotensin system, based on the different mechanisms of action of the two classes of drug. To assess the shortcomings of single treatment with ACEIs and ARBs, and the potential benefits of combination treatment, we reviewed the experimental and clinical evidence suggesting that combination treatment offers more complete blockade of the renin-angiotensin system and identified areas in which further research is necessary to confirm the benefits of combination treatment. The available data suggest that combination treatment with an ACEI and an ARB has a greater renoprotective effect than either drug alone. In addition, more recent data have shown that combination treatment is more potent in suppressing renal fibrosis, and is well tolerated in patients with advanced chronic kidney disease. Clinical trials with rigorous endpoints are needed to further establish the benefits of combination treatment in renal protection.
Collapse
Affiliation(s)
- Joon Ho Song
- Division of Nephrology and Hypertension, Inha University College of Medicine, Incheon, Korea.
| | | | | | | |
Collapse
|
19
|
Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 2006; 45:193-8. [PMID: 16543688 DOI: 10.2169/internalmedicine.45.1515] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
OBJECTIVE Evidence suggests that the effectiveness of angiotensin-converting enzyme (ACE) inhibition diminishes with time, resulting in increasing angiotensin II levels, the action of which can be inhibited by the addition of an angiotensin receptor blocker (ARB). In the present study, the renal protective effects of ACE inhibitors and ARBs were compared over a five-year period in a prospective, randomized, open-blind study in 68 nondiabetic Japanese patients with elevated serum creatinine levels. PATIENTS AND METHODS Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1.25 to 5 mg daily or trandolapril 0.5 to 4 mg daily) or ARB (candesartan 2 to 8 mg daily or losartan 25 to 100 mg daily) at the Kidney Disease Center at Saitama Medical School Hospital. The primary study endpoint was a change in glomerular filtration rate (GFR) between the baseline value and the last available value obtained during the five-year treatment period, as estimated by the Cockcraft-Gault equation. Secondary endpoints included the annual changes in GFR, serum creatinine level, urinary protein excretion, and blood pressure, as well as the rate of development of endstage renal disease. RESULTS There were no significant differences in the primary endpoint between the two groups. However, after 4 years, the decline in GFR in patients treated with ARBs was significantly greater than that seen in patients treated with an ACE inhibitor (p<0.05). Furthermore, the rate of introduction of dialysis therapy was also significantly greater in the ARB-treated patients (52.7% in ACE inhibitor and 81.2% in ARB group at year 5. p<0.01). CONCLUSION While our data suggested that ARB, like ACE, treatment might slow the progression of renal dysfunction, it also pointed to the necessity to be alerted to the progression to endstage renal disease with longterm medication.
Collapse
Affiliation(s)
- Junko Shoda
- Department of Nephrology, Saitama Medical School, Iruma, Saitama
| | | | | |
Collapse
|
20
|
Imai E. Is ACEI superior to ARB for CKD? Intern Med 2006; 45:179-81. [PMID: 16543686 DOI: 10.2169/internalmedicine.45.0141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
21
|
Günay EC, Oztürk MH, Ergün EL, Altun B, Salanci BV, Uğur O, Cil B, Hekimoğlu B, Caner B. Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing. Eur J Nucl Med Mol Imaging 2005; 32:1064-74. [PMID: 15875180 DOI: 10.1007/s00259-005-1789-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2004] [Accepted: 02/03/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE Radionuclide renography with angiotensin converting enzyme (ACE) inhibition plays an important role in the diagnosis of haemodynamically significant renal artery stenosis. Angiotensin receptor antagonists inhibit the renin angiotensin system at different levels from ACE inhibitors by selectively blocking the binding of angiotensin II to AT1 receptors. The AT1 angiotensin receptor antagonist losartan has recently been used clinically in the treatment of hypertension. However, the available data on the use of losartan with renography for the detection of renovascular hypertension are limited and contradictory. The purpose of this prospective study was to compare the effectiveness of losartan renography and captopril scintigraphy in revealing renal artery stenosis. METHODS A total of 61 renal units in 32 patients with hypertension were studied in two groups based on the losartan dosage (50 mg in group A and 100 mg in group B). Group A consisted of 17 patients, in whom 19 renal units had angiographically proven renal artery stenosis (>or=50%). In group B, there were 15 patients, in whom 20 renal arteries were stenotic. All of the patients underwent three renographies (baseline, captopril renography and early losartan renography). Early losartan renography was performed at 1 h after oral losartan administration in both groups. In group B, seven patients underwent additional losartan renography (late losartan) performed 3 h after oral losartan administration; these patients composed group B1. RESULTS The sensitivities of captopril and losartan studies were 63.2% and 42% in group A, 65% and 65% in group B and 55.6% and 66.6% in group B1, respectively. CONCLUSION From our preliminary results, we conclude that losartan is not superior to captopril renography for the detection of haemodynamically significant renal artery stenosis. However, a high dose (100 mg) of losartan provided higher sensitivity than the lower dose (50 mg). Late losartan scintigraphy provided similar diagnostic efficacy to early losartan renography.
Collapse
Affiliation(s)
- Emel Ceylan Günay
- Department of Nuclear Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004; 25:971-1010. [PMID: 15583025 DOI: 10.1210/er.2003-0018] [Citation(s) in RCA: 242] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
At present, diabetic kidney disease affects about 15-25% of type 1 and 30-40% of type 2 diabetic patients. Several decades of extensive research has elucidated various pathways to be implicated in the development of diabetic kidney disease. This review focuses on the metabolic factors beyond blood glucose that are involved in the pathogenesis of diabetic kidney disease, i.e., advanced glycation end-products and the aldose reductase system. Furthermore, the contribution of hemodynamic factors, the renin-angiotensin system, the endothelin system, and the nitric oxide system, as well as the prominent role of the intracellular signaling molecule protein kinase C are discussed. Finally, the respective roles of TGF-beta, GH and IGFs, vascular endothelial growth factor, and platelet-derived growth factor are covered. The complex interplay between these different pathways will be highlighted. A brief introduction to each system and description of its expression in the normal kidney is followed by in vitro, experimental, and clinical evidence addressing the role of the system in diabetic kidney disease. Finally, well-known and potential therapeutic strategies targeting each system are discussed, ending with an overall conclusion.
Collapse
Affiliation(s)
- Bieke F Schrijvers
- Medical Department M/Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark
| | | | | |
Collapse
|
23
|
Matsuda H, Hayashi K, Saruta T. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens 2003; 17:271-6. [PMID: 12692572 DOI: 10.1038/sj.jhh.1001543] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Although the angiotensin receptor antagonist (ARB) shares the angiotensin-II-blocking activity with the angiotensin-converting enzyme inhibitor (ACE-I), pharmacological mechanisms of action of these agents differ. We evaluated the temporal profiles of action of ACE-I and ARB on urinary protein excretion and nitrate/nitrate (NO(x)) excretion in hypertensive (140 and/or 90 mmHg) patients with chronic renal disease (serum creatinine < 265 (range, 44-265) micromol/l or creatinine clearance > 30 (range, 30-121) ml/min). Patients with mild (<1 g/day; range, 0.4-1.0) and moderate proteinuria (>1 g/day; range, 1.1-6.9) were randomly assigned to ACE-I- and ARB-treated groups, and were treated with ACE-I (trandolapril or perindopril) or ARB(losartan or candesartan) for 48 weeks. In all groups, treatment with ACE-I or ARB decreased blood pressure to the same level, but had no effect on creatinine clearance. In patients with mild proteinuria, neither ACE-I nor ARB altered urinary protein excretion. In patients with moderate proteinuria, ACE-I caused 44 +/- 6% reduction in proteinuria (from 2.7 +/- 0.5 to 1.5 +/- 0.4 g/day, n = 14) at 12 weeks, and this beneficial effect persisted throughout the protocol (48 weeks, 1.2 +/- 0.2 g/day). In contrast, ARB did not produce a significant decrease in proteinuria at 12 weeks (23 +/- 8%, n = 13), but a 41 +/- 6% reduction in proteinuria was observed at 48 weeks. Similarly, although early (12 weeks) increases in urinary NO(x) excretion were observed with ACE-I (from 257 +/- 70 to 1111 +/- 160 micromol/day) and ARB (from 280 +/- 82 to 723 +/- 86 micromol/day), the ARB-induced increase in NO(x) excretion was smaller than that by ACE-I (P < 0.05). In conclusion, although both ACE-I and ARB reduce blood pressure similarly, the effect of these agents on proteinuria differs in chronic renal disease with moderate proteinuria. Relatively early onset of the proteinuria-reducing effect was observed with ACE-I, which paralleled the increase in urinary NO(x) excretion. Conversely, ARB decreased proteinuria and increased urinary NO(x) excretion gradually. These time course-dependent changes in proteinuria and urinary NO(x) may reflect the pharmacological property of ACE-I and ARB, with regard to the action on bradykinin.
Collapse
Affiliation(s)
- H Matsuda
- Ashikaga Red Cross Hospital, Tochigi, Japan
| | | | | |
Collapse
|
24
|
Yokota K, Kishida M, Ogura T, Suzuki J, Otsuka F, Mimura Y, Takeda M, Nakamura Y, Makino H. Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. Hypertens Res 2003; 26:265-72. [PMID: 12675283 DOI: 10.1291/hypres.26.265] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
To elucidate whether bradykinin is involved in the renoprotective effect produced by angiotensin II type 1 receptor antagonist (AT1A) in chronic salt-sensitive hypertension, Dahl salt-sensitive rats receiving a high-salt (8%) diet were treated either with an AT1A (candesartan, 1 mg/kg/day), a bradykinin B2 receptor antagonist (BKB2A; FR172357, 30 mg/kg/day) or a combination of AT1A and BKB2A for 7 weeks. None of the treatments changed the markedly increased systolic blood pressure induced by a high-salt diet. However, chronic treatment with AT1A significantly improved the histological hallmarks of renal damage-i.e., glomerular sclerosis and cell proliferation-despite the presence of severe hypertension. This beneficial action of AT1A was abolished by the concomitant administration of BKB2A. In agreement with these histologically based findings, increases in levels of creatinine clearance induced by AT1A were also reversed back to the basal levels when BKB2A was administered in conjunction with AT1A. Furthermore, urinary excretions of nitrate plus nitrite and prostaglandin E2 increased moderately in response to the administration of AT1A alone, but not in combination with BKB2A. Thus, the blockade of bradykinin signaling abrogates the renoprotective actions of the angiotensin II type 1 (AT1) receptor antagonism. Collectively, these data show that when AT1 action is chronically blocked, endogenous bradykinin plays a pivotal role in preventing the progression of glomerular injury in salt-sensitive hypertension.
Collapse
Affiliation(s)
- Kazuaki Yokota
- Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, Tatematsu S, Wakino S, Saruta T. Differing Anti-Proteinuric Action of Candesartan and Losartan in Chronic Renal Disease. Hypertens Res 2003; 26:875-80. [PMID: 14714578 DOI: 10.1291/hypres.26.875] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
It has becoming clear that angiotensin receptor blockers (ARBs) show varying levels of angiotensin II type 1 (AT1) receptor blocking activity. Although the duration of activity and the efficacy on blood pressure of ARB are reported to vary, depending on the agents used, it has not been examined whether the effects on proteinuria and urinary nitrite/nitrate (NOx) excretion differ in hypertensive patients with chronic renal disease. In the present study, patients with hypertension (> 140 and/or 90 mmHg) and chronic renal disease (proteinuria > 0.5g/day; serum creatinine < 265 micromol/l or creatinine clearance > 30 ml/min/1.72 m2) were randomly assigned to perindopril- (n = 15), trandolapril- (n = 15), candesartan- (n = 17), and losartan-treated groups (n = 15), and were followed up for 96 weeks. All agents decreased blood pressure to the same level, and none of them had any effect on creatinine clearance. Candesartan, perindopril, and trandolapril reduced proteinuria markedly (from 3.0 +/- 0.6 to 1.8 +/- 0.5 g/day, 2.7 +/- 0.5 to 1.6 +/- 0.4 g/day, and 2.7 +/- 0.5 to 1.7 +/- 0.4 g/day, respectively) at 12 weeks, and the beneficial effect persisted throughout the study. The effect of losartan, however, diminished over the study period. Whereas perindopril, trandolapril, and candesartan markedly increased urinary NOx excretion (from 257 +/- 23 to 1,011 +/- 150 micromol/day, 265 +/- 70 to 986 +/- 130 micromol/day, and 260 +/- 62 to 967 +/- 67 micromol/day at 12 weeks, respectively), a relatively blunted increase was observed with losartan (from 309 +/- 42 to 596 +/- 64 micromol/day). In conclusion, renal action of ARB varies, with relatively less proteinuria-sparing, as well as NOx-enhancing, effects observed with candesartan showing the greatest reduction of proteinuria and greatest enhancement of NOx. Furthermore, renal nitric oxide may contribute to the renal protective action of these agents when administered to patients with chronic renal disease.
Collapse
|
26
|
Liu Y, Zhuoma C, Shan G, Cui C, Hou S, Qin W, Cai D, Gesang L, Xiao Z, Pingcuo Z, Zheng H, Wu Z, Zhou W, Qiu C. A1166C polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in Han, Tibetan and Yi populations. Hypertens Res 2002; 25:515-21. [PMID: 12358135 DOI: 10.1291/hypres.25.515] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Our aim was to clarify whether substitution of cytosine for adenine at position 1166 (A1166C) polymorphism of the angiotensin II type 1 receptor (AT1R) gene is associated with susceptibility to essential hypertension in Han, Tibetan and Yi populations in China. This study involved 302 normotensive and 446 hypertensive subjects. The polymorphism was detected by polymelase chain reaction of genomic DNA and restriction fragment length polymorphism (PCR-RFLP) in genomic DNA. The data were analyzed by analysis of covariance (ANCOVA), X2 test, and multiple logistic regression. In normotensive controls, the A1166 allele frequencies were 0.979, 0.939 and 0.965 in Han, Tibetan and Yi participants, respectively. There was no significant intergroup variation in frequency of the allele in normotensives (X2=4.166, p=0.125). The frequency of the A1166 allele was significantly higher in Tibetan male hypertensives than that in normotensives (X2=11.46, p=0.001). There was no significant difference in A1166C genotype distribution and allele frequency between normotensives and hypertensives either in the Han (p=0.465) or Yi (p=0.357) populations. Body mass index in the Han and Yi populations (p=0.0001), age in the Tibetan and Yi populations (p=0.0001), and AA genotype in the Tibetan male population (p=0.0034) all were independent risk factors for hypertension. Diastolic blood pressure levels were significantly higher in Tibetan male subjects with the AA genotype than in those with the AC+CC genotype (p=0.0040). We concluded that the A1166 allele is very common in Han, Tibetan and Yi populations, approximately 1.35-fold more common than in Caucasians. The A1166 allele of the AT1R gene may be a predisposing factor for essential hypertension in Tibetan males. A1166C polymorphism of the AT1R gene is probably not involved in the pathogenesis of essential hypertension in Han or Yi populations.
Collapse
Affiliation(s)
- Ying Liu
- National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|